A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

Inclusion Criteria:

1. Ability and willingness to participate in the study, give written informed consent,and comply with the study specific requirements and all protocol procedures.

2. Sex: male or female; Age: 18 to 75 years, inclusive

3. BMI: 20.0 kg/m^2 to 35.0 kg/m^2, inclusive

4. Have been diagnosed with T2DMthat is inadequately controlled with at least 3 monthsof diet and exercise prior to screening.

5. HbA1c ranging from 7.5% to 11.0% at screening, inclusive

6. FPG ≤13.9 mmol/L at screening.

Exclusion Criteria:

1. History of type 1 or other types of diabetes mellitus.

2. Use of any GLP-1 analogue during the 3 months preceding to screening.

3. History of proliferative diabetic retinopathy, diabetic maculopathy, diabeticneuropathy, or diabetic foot during the 6 months preceding screening.

4. History of acute or chronic pancreatitis or high risk factors for pancreatitis.

5. Personal or family history of medullary thyroid carcinoma or multiple endocrineneoplasia syndrome type 2.

6. History of stomach surgeries or disorders associated with slowed emptying of thestomach during the past 6 months.

7. History of heart attack, stroke, or congestive heart failure of Grade 3 or 4 in thepast 6 months.